Revolutionizing Tumor Treatment: MedGenome Launches India's First CNS Tumor Methylation Classifier Test

MedGenome has introduced the first CNS Tumor Methylation Classifier Test in India. This innovative diagnostic tool can distinguish over 90 brain and CNS tumor classes, aiding precise treatment. Employing DNA methylation profiling, it complements traditional techniques and was launched at a symposium attended by global experts.

City-based company MedGenome has announced the launch of India's first CNS Tumor Methylation Classifier Test, a groundbreaking development in the field of genomic diagnostics.

This innovative test can differentiate and classify over 90 classes of brain and central nervous system tumors into precise subtypes, assisting doctors in making optimal treatment choices. The test utilizes DNA methylation profiling to examine chemical modifications across the genome, creating unique tumor profiles.

The announcement was made during a symposium in Mumbai attended by various experts, highlighting MedGenome's global presence and advanced capabilities in genetic testing, particularly through its largest CAP-accredited lab in South Asia.

(With inputs from agencies.)